Multiple myeloma (MM) is not a disease with a known cure, but recent studies have suggested that focusing on boosting immunity in patients with MM may help their chances at longer-term survival. What are these immunity-focused treatment options?
Researchers sought to determine whether subcutaneous daratumumab would require less HCP time and would be a more efficient method for administering the drug.
Researchers sought to determine whether combination therapies with carfilzomib would be feasible for patients with relapsed/refractory multiple myeloma.
A single-center study found anti-COVID-19 protection lowest in patients with MM at 2 weeks after their second BNT162b2 mRNA shot than did patients with myeloproliferative malignancies, and was highest in older patients without cancer.
Researchers sought to determine the real-world renal function and outcomes for patients with multiple myeloma according to type of treatment and line of therapy.
Researchers sought to determine whether poorer health-related quality of life would be linked to responses about pain severity in patients with multiple myeloma.
